Novartis cancer drug wins wider U.S. approval

Swiss drugmaker Novartis AG won wider U.S. approval for its leukemia drug Tasigna to treat a rare form of the blood cancer at an earlier stage of the disease, the Food and Drug Administration said on Thursday.